Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C. M. Jol-van der Zijde is active.

Publication


Featured researches published by C. M. Jol-van der Zijde.


The Journal of Infectious Diseases | 1999

Quality and Quantity of the Humoral Immune Response in Healthy Elderly and Young Subjects after Annually Repeated Influenza Vaccination

I. A. de Bruijn; E.J. Remarque; C. M. Jol-van der Zijde; M. J. D. Van Tol; R.G.J. Westendorp; D. L. Knook

Doubt about the serologic efficacy of annually repeated influenza vaccination prompted investigations into the course of hemagglutination-inhibiting (HI), IgG, and IgA antibody titers and the IgG and IgA avidity index to influenza A/Taiwan/1/86 and A/Beijing/353/89 after annual vaccination. Fifty-four healthy elderly persons >70 years of age and 24 healthy young adults <30 years of age received standard influenza vaccine during 3 consecutive years. On average, prevaccination HI, IgG, and IgA titers to both influenza virus strains increased >=4 fold between the first and the third vaccination (analysis of variance, P<.001). The postvaccination HI and IgG titers remained unchanged after annual vaccination. The avidity index of IgG and IgA antibodies increased somewhat after annual vaccination, although the increase was statistically significant only in the young subjects. These data indicate that annual influenza vaccination of healthy elderly and young subjects results in an overall increase in protective antibodies.


Bone Marrow Transplantation | 2005

Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery

M. J. D. Van Tol; Aloys C. M. Kroes; J Schinkel; W Dinkelaar; Eric C. J. Claas; C. M. Jol-van der Zijde; Jaak M. Vossen

Summary:Adenovirus (HAdV) infections are a frequent cause of morbidity and mortality after allogeneic human stem cell transplantation (HSCT). We report a retrospective single-centre study on 328 consecutive paediatric recipients of an allogeneic HSCT. During the first 6 months after HSCT, HAdV infection occurred in 37 children (cumulative incidence 12%). The highest incidence was found in young children up to 5 years of age, transplanted after 1994, with >2 log T-cell depletion of a graft of another than an HLA-genotypically identical related donor (actuarial frequency at 6 months 84%). Persistence of HAdV and spreading of the virus over multiple sites showed a trend towards the development of HAdV disease or death, but did not reach significance. Recovery of immunity after HSCT, that is, serum concentrations of IgM and peripheral blood counts of T cells and subsets, was delayed in children with an HAdV infection compared with noninfected children. In seven out of seven patients with HAdV DNA in serum and decreasing lymphocyte counts, the infection had a fatal course. Manipulation of cellular immunity either by tapering of immunosuppression, infusion of donor lymphocytes or immunotherapy using HAdV-specific T cells should be considered in graft recipients at risk for a severe HAdV infection.


Journal of Neuroimmunology | 2008

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1

Erik H. Niks; Y. van Leeuwen; M I Leite; Friedo W. Dekker; Axel R. Wintzen; Paul W. Wirtz; Angela Vincent; M. J. D. Van Tol; C. M. Jol-van der Zijde; Jan J. Verschuuren

We studied the longitudinal relation between disease severity and titers of antigen-specific IgG subclasses in sera of patients with myasthenia gravis and antibodies to Muscle Specific Kinase (MuSK MG). Six patients were included of whom 55 samples had been collected during 2.5-13.4 years. Anti-MuSK antibodies were determined by ELISA and with a cell-based immunofluorescence assay. Disease severity was scored on a semi continuous scale. Only antigen-specific IgG4, and not IgG1, titers were significantly associated with disease severity in a linear mixed effect model (p = 0.036). Levels of IgG4 antibodies were above IgG1 in all samples except in one patient who went into clinical remission while switching from IgG4 to IgG1. The results support an important role for IgG4 in the pathogenesis of MuSK MG, in contrast to MG with anti-acetylcholine receptor antibodies.


Arthritis & Rheumatism | 2012

Avidity maturation of anti–citrullinated protein antibodies in rheumatoid arthritis

Parawee Suwannalai; L. A. van de Stadt; Helga Radner; Günter Steiner; Hani El-Gabalawy; C. M. Jol-van der Zijde; M. J. D. Van Tol; D. van Schaardenburg; T. W. J. Huizinga; René E. M. Toes; Leendert A. Trouw

OBJECTIVE Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) and are present years before the onset of symptoms. The avidity of autoantibodies can have a strong impact on their effector potency. This study was undertaken to analyze the avidity of ACPAs in serum samples obtained from ACPA-positive healthy individuals (predisease), patients with early disease, and patients with established RA as well as the avidity maturation over time in samples from healthy subjects who later developed RA. METHODS We measured ACPA avidity in serum samples from ACPA-positive healthy individuals, symptomatic individuals, and patients with established RA in 5 collections from The Netherlands, Canada, and Austria. We determined the dynamics of avidity maturation of ACPAs from the predisease stage to established disease in 1 case from the native North American population and in 10 cases from a Dutch blood donor cohort. RESULTS The overall ACPA response was characterized by low-avidity antibodies. Higher-avidity ACPAs were observed in symptomatic patients only, while low-avidity ACPAs were observed in both healthy subjects and patients. In longitudinal samples obtained from subjects prior to disease onset, ACPA avidity increased over time until disease onset. No further avidity maturation was observed after disease onset. CONCLUSION Our findings indicate that avidity maturation of the ACPA response takes place prior to disease onset.


Annals of the Rheumatic Diseases | 2010

Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens

Parawee Suwannalai; Hans Ulrich Scherer; D. van der Woude; Andreea Ioan-Facsinay; C. M. Jol-van der Zijde; M. J. D. Van Tol; Jan W. Drijfhout; T. W. J. Huizinga; René E. M. Toes; Leendert A. Trouw

Objectives Anti-citrullinated protein antibodies (ACPA) are highly specific for rheumatoid arthritis (RA) and have been implicated in disease pathogenesis. Recent ongoing evidence indicates that the ACPA response broadens before precipitation of full-blown RA, as indicated by a more extensive isotype usage and an increased citrullinated epitope recognition profile. Nonetheless, the evolution of the ACPA response is still poorly understood and might intrinsically differ from the protective responses against pathogens. Methods The avidity and the avidity maturation of ACPA in relation to the avidity of antibodies against recall antigens were analysed. Results The avidity of ACPA was significantly lower than the avidity of antibodies to the recall antigens tetanus toxoid and diptheria toxoid. Moreover, ACPA did not show avidity maturation during longitudinal follow-up and ACPA avidity was also relatively low in patients who displayed extensive isotype switching. Conclusions These observations indicate that the natural evolution of ACPA differs from the development of antibodies against recall antigens. These data also indicate that ACPA avidity maturation and isotype switching are disconnected, whereby extensive isotype switching occurs in the setting of restricted avidity maturation. Intrinsic differences between the RA-specific autoantibody system and protective antibody responses against pathogens could be of relevance for designing novel B cell-targeted therapies for RA.


Neurology | 2008

A transient neonatal myasthenic syndrome with anti-musk antibodies.

Erik H. Niks; Aad Verrips; B. A. Semmekrot; M.J.J. Prick; Angela Vincent; M. J. D. Van Tol; C. M. Jol-van der Zijde; J. Verschuuren

Some patients with myasthenia gravis (MG) have autoantibodies to muscle specific kinase (MuSK) instead of the acetylcholine receptor (AChR). Anti-AChR antibodies may be transferred across the placenta causing a self-limiting neonatal myasthenic syndrome. We describe an infant with a similar disorder whose mother had MuSK MG. ### Case report. In September 1994, the mother noticed unilateral ptosis and a feeling of generalized fatigue at age 13. Over the next months, she developed severe oculobulbar weakness, dyspnea, and weakness of the neck. Symptoms were fluctuating and unresponsive to acetylcholinesterase inhibitors. No antibodies to the AChR were found. In 1995, a normal thymus was removed. High doses of prednisone had little effect. In 1997, plasmapheresis induced a partial remission and this became her regular therapy for several years. In 2004 anti-MuSK antibodies were found. She had two first trimester miscarriages while using pyridostigmine and prednisone in September and December 2004. In May 2005, she became pregnant using only prednisone 20 mg on alternating days. This pregnancy was uneventful without large fluctuations of her myasthenic symptoms. In February 2006, at 38 + 1 week of gestation, she unaidedly delivered a boy in head position. Apgar score was 10 after 1 and 5 minutes. Birthweight was 3,190 g (P25). Physical examination was unremarkable. After 8 hours, however, drinking became difficult. After 16 hours, he showed mild generalized hypotonia with diminished facial expression …


Journal of Clinical Immunology | 2003

Vaccination with Rabies to Study the Humoral and Cellular Immune Response to a T-Cell Dependent Neoantigen in Man

D. M. C. Brinkman; C. M. Jol-van der Zijde; M. M. ten Dam; Jaak M. Vossen; A. D. M. E. Osterhaus; Frank P. Kroon; M. J. D. Van Tol

We investigated the humoral (antigen-specific immunoglobulin isotypes, IgG subclasses, and avidity maturation) and cellular (antigen-specific in vitro proliferation) immune response in 18 healthy adult volunteers, following a primary and a single booster vaccination with the T-cell dependent neoantigen rabies administered at a 3-months interval. The IgG antibody titer showed a mean 31-fold increase (range 3–154) 4 weeks after the first vaccination and a memory response was observed after booster vaccination, i.e. high IgG titers, switch from IgM to IgG and IgA and increased antibody avidity. All healthy adults showed a rabies-induced proliferative response with a mean stimulation index of 45 (range 3.5–200) after in vitro stimulation of PBMC obtained at 4 weeks after booster vaccination. The results obtained in this study provide a frame of reference for the interpretation of specific immune responses to the T-cell dependent neoantigen rabies in patients suspected of a primary or secondary immunodeficiency. Humoral and cellular immune responses to the rabies neoantigen provide complementary information on the condition of the immune system of an individual. Five patients diagnosed with a combined immunodeficiency were vaccinated using the same protocol and showed a number of abnormalities, either in the humoral or the cellular immune response to the rabies neoantigen.


Clinical and Experimental Immunology | 2003

Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood

Petra M.C. Callenbach; C. M. Jol-van der Zijde; Ada T. Geerts; W.F.M. Arts; C. A. van Donselaar; Peters Ac; Hans Stroink; Oebele F. Brouwer; M. J. D. Van Tol

In an unselected cohort of 282 children, serum immunoglobulin (Ig) concentrations were determined shortly after the first presentation with one or more unprovoked epileptic seizures and before the start of treatment with anti‐epileptic drugs (AEDs), and after 9–18 months of AEDs use. At intake, IgA, IgG1, IgG2 and IgG4 concentrations were significantly higher than published reference values in healthy age‐matched controls. In a subset of 127 children, Ig levels at intake were compared with those after AEDs use for 9–18 months. IgA and IgG4 levels had decreased significantly to normal concentrations, but IgG1 and IgG3 levels increased significantly. To determine the influence of AEDs, Ig levels in children who used carbamazepine or valproic acid monotherapy were analysed separately. The use of carbamazepine was associated with a significant decrease of IgA and IgG4 levels, and the use of valproic acid with a significant decrease of IgA and increase of IgG1 levels. In conclusion, humoral immunity is already altered in children shortly after the first presentation with epileptic seizures. Whether this is the consequence of an exogenous event, and to what extent this is related to an interaction of the central nervous system and the immune system, remains to be evaluated. Treatment with AEDs, such as carbamazepine and valproic acid, is associated with significant changes of Ig (sub)class concentrations.


Journal of Clinical Immunology | 2007

Resetting the Adaptive Immune System After Autologous Stem Cell Transplantation: Lessons from Responses to Vaccines

D. M. C. Brinkman; C. M. Jol-van der Zijde; M. M. ten Dam; P. A. W. te Boekhorst; R ten Cate; N. M. Wulffraat; Rogier Q. Hintzen; Jaak M. Vossen; M. J. D. Van Tol

Autologous stem cell transplantation (ASCT) to treat autoimmune diseases (AID) is thought to reset immunological memory directed against autoantigens. This hypothesis can only be studied indirectly because the exact nature of the pathogenetic autoantigens is unknown in most AID. Therefore, 19 children with juvenile idiopathic arthritis (JIA) or systemic lupus erythematodes (SLE) and 10 adults with multiple sclerosis (MS) were vaccinated with the T-cell-dependent neoantigen rabies and the recall antigen tetanus toxoid after, respectively before, bone marrow harvest. Both vaccinations were repeated after ASCT. All except two of the responders mounted a primary antibody response to rabies after revaccination, and 44% of the responders mounted a primary antibody response to tetanus boost after ASCT. These data show that immunological memory to a neoantigen is lost in most patients with AID after immunoablative pretreatment; however, memory to a recall antigen boosted before bone marrow harvest is only lost in part of the patients. Disease progression was arrested in all patients with JIA/SLE except one, but only in a minority of MS patients. Clinical outcome on a per case basis was not associated with the profile of the immune response toward the vaccination antigens after ASCT.


Vaccine | 2008

Cellular and humoral responses to tetanus vaccination in Gabonese children.

E. van Riet; Kim Retra; Ayola A. Adegnika; C. M. Jol-van der Zijde; H.-W. Uh; Bertrand Lell; Saadou Issifou; Peter G Kremsner; Maria Yazdanbakhsh; M. J. D. Van Tol; Franca C. Hartgers

Protection to tetanus is often not optimal in developing countries due to incomplete vaccination schemes, or decreased efficacy of vaccination. In this study we investigated the immunological response to tetanus booster vaccination in school children living in a semi-urban or in a rural area of Gabon. Tetanus-specific total IgG as well as antibody subclasses of the IgG1, IgG2, IgG3 and IgG4 isotype and the avidity of the dominating IgG1 subclass were determined both before and 1 month after the booster vaccination. In addition, tetanus-specific cytokine responses were determined. We found a polarization towards a T helper 1 (Th1) profile in the semi-urban children, whereas the cytokine responses of the rural children showed a T helper 2 (Th2) skewed response. Furthermore, tetanus-specific antibodies of the different IgG subclasses were all increased upon a tetanus booster vaccination and levels of IgG1 and IgG3 were higher in the rural children. In conclusion, a tetanus booster vaccination induced a stronger Th2 over Th1 cytokine profile to tetanus toxoid (TT) in rural children who showed the highest levels of IgG1 and IgG3 anti-TT antibody responses.

Collaboration


Dive into the C. M. Jol-van der Zijde's collaboration.

Top Co-Authors

Avatar

M. J. D. Van Tol

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

René E. M. Toes

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

T. W. J. Huizinga

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leendert A. Trouw

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arjan C. Lankester

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

D. M. C. Brinkman

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jaak M. Vossen

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jan W. Drijfhout

Leiden University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge